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HypoglycemiaAims: A number of insulin regimens are used in type 2 diabetes. This analysis aims to bet-
ter understand the evolution of insulin therapy in different regions of Europe.
Methods: Data from people starting any insulin were collected in eastern Europe (EEur:
Croatia, Russia, Ukraine), northern Europe (NEur: Finland, Germany, UK) and southern Eur-
ope (SEur: France, Italy, Portugal, Spain). Retrospective data on starting insulin and
prospective follow-up data were extracted from clinical records.
Results: At 4 years, 1699 (76.0%) of 2236 eligible people had data. EEur participants were
mostly female, younger and had shorter diabetes duration on starting insulin, yet had high-
est baseline HbA1c and more micro-/macrovascular disease. A majority (60%–64%) in all
regions started on basal insulin alone, declining to 30%–38% at 4 years, with most switching
to basal + mealtime insulin regimen (24%–40%). Higher baseline (28%) and 4-year use (34%)
of premix insulin was observed in NEur. Change in HbA1c (SD) ranged from 1.2 (2.1)% (13
[23] mmol/mol) in NEur to 2.4 (2.0)% (26 [22] mmol/mol) in EEur. Weight change ranged
from +1.9 (8.3) kg in NEur to +3.2 (7.0) kg in SEur. Overall documented hypoglycemia ranged
from 0.3 (1.3) to 1.3 (4.4) events/person/6-months (NEur vs. EEur, respectively) and was
stable with time. Severe hypoglycemia rates remained low.
Conclusion: When starting insulin, HbA1c and prevalence of complications were higher in
EEur. Regional differences exist in choice of insulin regimens in Europe. However, people
starting insulin improved and sustained their glycemic control regardless of regional differ-
ences or insulin regimens used.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).LA 70121,
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Insulin therapy is generally started when people with type 2
diabetes on oral therapies can no longer attain the recom-
mended targets for blood glucose control. Various types of
insulin have been recommended [1–3], with some authorities
sanctioning basal or premix, while others emphasize basal
insulin only. Mealtime insulin alone is occasionally recom-
mendedwhen starting insulin as is a mealtime + basal insulin
regimen [4]. Evidence on the relative efficacy of insulin regi-
mens has been provided in randomized clinical trials [5,6],
but these trials may not be representative of the people and
clinical environments found in routine clinical practice. Some
of the challenges of generalizability intrinsic to randomized
trials may be overcome in non-interventional observational
studies, and they may be a bridge toward more routine clini-
cal settings [4].
The Cardiovascular Risk Evaluation in People With Type 2
Diabetes on Insulin Therapy (CREDIT) study, an interna-
tional, 4-year, non-interventional, longitudinal study, was
designed to evaluate, in routine clinical practice, the rela-
tionship between blood glucose control and cardiovascular
events in people beginning any insulin and to provide
insight into current medical practice in people with type 2
diabetes using insulin [7]. The study was conducted in
Canada, Japan and 10 countries in Europe from December
2006 to May 2012. Baseline data and 1- and 4-year blood
glucose-related results have been reported in detail for the
overall population [7–10].
The aim of the current study was to dissect out some of the
differences in clinical practice when starting insulin in differ-
ent parts of Europe, specifically in terms of the population
starting insulin, insulin regimens used, and concomitant ther-
apies, and resultant outcome. We hoped to gain a better
understand of the diversity of clinical behavior and perhaps
shed light on the reasons for some of the differences. Tomain-
tain reasonable pools of data, we report blood glucose-related
outcomes at 4 years in study-defined regions of eastern (E),
northern (N) and southern (S) Europe, concentrating on char-
acteristics when starting insulin, choice of insulin regimen,
evolution of insulin therapy and metabolic outcomes.
2. Materials and methods
The CREDIT study design, site/participant selection pro-
cess and participant baseline characteristics have been
reported previously [7]. Ethical approval was obtained
for all study sites. Study conduct adhered to data collec-
tion standards for clinical trials, according to the Declara-
tion of Helsinki. All participants gave written informed
consent prior to enrollment. Men and women aged
>40 years with type 2 diabetes were eligible if they had
started any insulin regimen >1 month and <12 months
prior to study entry and had an HbA1c measurement
within 3 months before beginning insulin. Data when
starting insulin were collected retrospectively from
clinical records and included micro-/macrovascular dis-
ease and high blood pressure as well as starting insulin
regimen. Microvascular disease was defined as havingnephropathy, retinopathy and/or peripheral neuropathy.
Macrovascular disease was defined as having myocardial
infarction, stable angina, severe unstable angina leading
to hospitalization, heart failure, stroke, transient ischemic
attack, peripheral vascular disease, myocardial revascular-
ization, peripheral revascularization and/or lower limb
amputation. High blood pressure was defined as
130/80 mmHg.
Starting insulin regimens were classified as basal, basal
+ mealtime, mealtime, premix and other, where other was a
mix of these. There was no fixed study visit schedule, and
insulin choice, dosage, titration and concomitant oral agent
therapy were according to usual local practice. Data were
gathered from routine clinical practice from people starting
any insulin in E Europe (Croatia, Russia, Ukraine), N Europe
(Finland, Germany, United Kingdom) and S Europe (France,
Italy, Portugal, Spain).
Physicians were asked to report updated data every
6 months. Data at 1, 2, 3 and 4 years represent those ascer-
tained 9–18, 18–30, 30–42, and 42–54 months after starting
insulin, respectively. Glucose control was assessed by HbA1c,
fasting plasma glucose (FPG) and postprandial plasma glu-
cose (PPPG). HbA1c is presented in both National Glycohe-
moglobin Standardization Program and International
Federation of Clinical Chemistry units, locally measured
[11,12]. FPG and PPPG are reported as either laboratory- or
self-monitored glucose values. PPPG values were obtained
approximately 2 h post-meal. Documented symptomatic
hypoglycemia, nocturnal hypoglycemia and severe hypo-
glycemia were assessed retrospectively over the 6 months
prior to the follow-up visit date. Symptomatic hypoglycemia
was an event with clinical symptoms confirmed by blood
glucose 3.9 mmol/l. Nocturnal hypoglycemia was hypo-
glycemia that occurred while the patient was asleep, after
bed-time and before getting up in the morning. Severe hypo-
glycemia was an event that required assistance of another
person and either confirmed blood glucose <2.0 mmol/l or
prompt recovery after oral carbohydrate, intravenous glu-
cose or glucagon administration. Changes of insulin regi-
men, other glucose-lowering medications and body weight
change were assessed.
2.1. Statistical methods
Analyses were performed with SAS software, version 9.2
(Cary, NC, USA). All data are reported and analyzed using
descriptive statistics. All data (when starting insulin and
yearly data) are presented for each regional population. The
percentage and 95% CIs of participants on individual insulin
regimens are presented for each regional population. Com-
parative statistical testing was not performed because of the
likelihood of some degree of allocation bias, avoiding the dan-
ger of spurious statistically significant findings with the high
numbers of people studied.3. Results
A total of 2236 (74.6%) of the 2999 eligible participants were
from Europe: 735 from E Europe, 460 from N Europe and
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ticipants, 1699 (76.0%) had 4-year data. There were differences
in baseline characteristics between regions (Table 1). More
participants from E Europe were female, younger and had
shorter diabetes duration, yet had higher HbA1c and had
more micro-/macrovascular disease when beginning insulin
than those from the other regions. In each region, the base-
line characteristics of participants without 4-year data were
similar to those of all participants in that region (Supplemen-
tal Table 2).
Across the regions, 73%–100% of the 228 physicians were
specialists (diabetologist/endocrinologist/internist) in an
urban location (68–100%). The percentage of physicians with
their practice office-based, hospital-based or both was
25.0%, 43.8% and 31.3% in E Europe; 40.0%, 52.5% and 7.5%
in N Europe; and 48.9%, 16.8% and 34.3% in S Europe. Most
physicians were males in N Europe (65.0%) and S Europe
(55.1%), whereas 91.8% were female in E Europe.Table 1 – Demographic and clinical characteristics when startin
E Europe
Age, years 58 (8)
Female, n (%) 554 (75)
Body weight, kg 83.0 (15.5)
Body mass index, kg/m2 30.7 (5.4)
Duration of diabetes, years 8 (5)
1 microvascular disease, n (%) 633 (86)
1 macrovascular disease, n (%) 346 (47)
Prior diagnosis of high blood pressure, n (%) 574 (78)
Family history of premature CVD, n (%) 337 (46)
Physical exercise, n (%) 465 (63)
Never smoked/stopped smoking 1 year, n (%) 653 (89)
Other glucose-lowering medication, n (%)
1 547 (74)
1 320 (44)
2 220 (30)
3 7 (1)
Metformin 317 (43)
Sulfonylurea 417 (57)
Glinides 21 (3)
Thiazolidinediones 24 (3)
a-Glucosidase inhibitor 2 (0.3)
GLP-1 receptor agonist 0 (0)
DPP-4 inhibitor 0 (0)
Other 0 (0)
1 other long-term treatmenta, n (%) 631 (86)
HbA1c, % 9.7 (1.9)
HbA1c, mmol/mol 83 (21)
FPG, mmol/l 11.7 (3.1)
PPPG, mmol/l 13.7 (3.6)
Managing physician (n (%))
Primary care/generalist 0 (0.0)
Specialist 722 (100.0
Type of practice (n (%))
Office-based 189 (26.6)
Hospital-based 335 (47.2)
Both 186 (26.2)
Mean (SD) or n (%).
a Includes a-blockers, b-blockers, calcium channel blockers, diuretics, an
nitrates), statins, fibrates, antiplatelets and anticoagulants.3.1. Insulin regimens
Approximately 60%–64% of participants in all three regions
initiated insulin with only a basal formulation, and use of this
at 4 years had declined in all to 30%–38% of participants, with
the biggest fall in N Europe (Fig. 1). A basal + mealtime regi-
men had the greatest use at baseline in E Europe (15%) and
had a slightly lower use in S Europe. However, there was a
marked increase in use of this regimen in all regions by
4 years, again most notably in E Europe (40% at 4 years), with
the least increase in N Europe. Premix insulin had the greatest
baseline use in N Europe (28%), expanding by 4 years to 34%,
but with no change in E Europe (22% at both times) and little
change (13%–16%) in S Europe. Accordingly, participants in all
regions appear to be moving primarily to a basal bolus regi-
men with time. Few participants in any region started on
mealtime (2%–5%) or ‘‘other” insulin regimens (0.4%–6%), with
proportions remaining below 10% at 4 years. However, whileg insulin by region in Europe.
(n = 735) N Europe (n = 460) S Europe (n = 1041)
63 (11) 63 (11)
178 (39) 458 (44)
90.0 (19.4) 79.8 (16.7)
31.5 (6.3) 29.5 (5.9)
9 (6) 13 (9)
291 (63) 571 (55)
161 (35) 308 (30)
350 (76) 684 (66)
132 (29) 159 (15)
223 (49) 398 (38)
353 (77) 857 (82)
359 (78) 743 (71)
178 (39) 315 (30)
159 (35) 339 (33)
22 (5) 89 (9)
305 (66) 577 (55)
200 (43) 445 (43)
9 (2) 110 (11)
41 (9) 71 (7)
4 (0.9) 52 (5.0)
0 (0) 0 (0)
2 (0.4) 0 (0)
2 (0.4) 9 (0.9)
424 (92) 851 (82)
9.1 (2.0) 9.3 (1.9)
76 (22) 78 (21)
10.6 (3.4) 11.9 (3.9)
14.3 (5.3) 13.7 (4.4)
107 (23.3) 141 (13.6)
) 353 (76.7) 892 (86.4)
219 (47.6) 371 (35.9)
210 (45.7) 392 (37.9)
31 (6.7) 270 (26.1)
giotensin II receptor blockers/ACE inhibitors, vasodilators (including
Fig. 1 – Evolution of basal, basal + mealtime and premix
insulin regimens over 4 years in E Europe (A), N Europe (B),
and S Europe (C). Not shown are the least used insulin
regimens. Respectively, mealtime insulin was 2.2%, 3.9%
and 5.3% (start) and 0.3%, 4.2% and 1.0% (4-year) in E Europe,
N Europe and S Europe, and ‘‘other” insulin was 0.7%, 0.4%
and 6.4% (start) and 1.3%, 0.6% and 8.9% (4-year). At 4 years,
‘‘no insulin” was 0.3%, 7.2% and 4.4% in the respective
regions.
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true of 4% in S Europe but <1% in E Europe. Few in N Europe
started on a basal + mealtime insulin regimen (7%), while
few in S Europe started on premix (13%). For participants with
4 years of data, 52% in E Europe, 63% in N Europe and 59% in S
Europe remained on their starting regimen for all 4 years.
More of these participants across regions (48%–61%) remained
on basal insulin than any other regimen; in N Europe, 39%
also remained on premix.
At 4 years, more participants in E Europe were prescribed
basal insulin alone (42% vs 26%), basal + mealtime insulin
(43% vs 32%) and pre-mix insulin (62% vs 20%) by hospital-
based rather than office-based physicians. In N Europe, moreparticipants were prescribed basal insulin alone (61% vs 20%)
and basal + mealtime insulin (64% vs 33%) by office-based
physicians, whereas more were prescribed pre-mix insulin
by hospital-based physicians (63% vs 33%). In S Europe, more
participants were prescribed basal insulin alone (49% vs 22%)
and pre-mix insulin (36% vs 24%) by office-based physicians,
whereas more were prescribed basal + mealtime insulin
(68% vs 21%) and other insulin (55% vs 27%) by hospital-
based physicians. The percentage of participants prescribed
an insulin regimen by physicians with both an office- and
hospital-based practice ranged from 17%–32% in E Europe;
2.5%–11% in N Europe; and 18%–40% in S Europe, with the
highest percentage observed with basal insulin alone in E Eur-
ope and N Europe and with pre-mix insulin in S Europe. Over-
all, similar results were observed when starting insulin.
3.2. Other glucose-lowering medications
Of the eligible participants starting insulin, 71%–78% were
taking 1 other glucose-lowering medication across regions
(Table 1). The proportion of participants taking only one other
glucose-lowering medication when starting insulin ranged
from 30% in S Europe to 44% in E Europe, while a similar pro-
portion across regions were taking two other medications
(30%–35%). Those taking 3 other glucose-lowering medica-
tions ranged from 1% in E Europe to 9% in S Europe. Met-
formin use was lower (43%) and sulfonylurea use greater
(57%) in E Europe than in the other regions; use of glucose-
lowering medications other than metformin or sulfonylurea
was limited in all regions.
Across regions at 4 years, 62%–67% were taking 1 other
glucose-lowering medication (Table 2). Similar proportions
of participants were taking one (37%–44%) or two (15%–22%)
other glucose-lowering medication across regions, while
those taking 3 other medications ranged from 0.4% in E Eur-
ope to 8% in S Europe. Metformin use across regions at 4 years
was similar to that when starting insulin, whereas sulfony-
lurea use across regions declined to 15%–29%. Use of
glucose-lowering medications other than metformin or sul-
fonylurea, while still low, did increase in all regions. This
increase was predominantly due to use of
dipeptidylpeptidase-4 (DPP-4) inhibitors in E Europe and to
DPP-4 inhibitors and glucagon-like peptide-1 receptor (GLP-
1R) agonists in N and S Europe.
3.3. Insulin dose
The mean (SD) total daily starting dose of insulin was lower in
N Europe (0.20 [0.18] U/kg) than in E Europe (0.29 [0.19] U/kg)
and S Europe (0.27 [0.18] U/kg in). However, the greatest
increase to the highest level at 4 years was in N Europe (0.64
[0.46] U/kg), with lesser but similar changes in the other two
regions (Table 2; Fig. 2).
3.4. Blood glucose control
Mean (SD) HbA1c when starting insulin was highest in E
Europe (9.7 [1.9]%; 83 [21] mmol/mol) and lowest in N Europe
(9.1 [2.0]%; 76 [22] mmol/mol) (Fig. 2). However, by 4 years
this reversed, being the lowest in E Europe (7.3 [1.1]%; 56
Table 2 – Glucose-lowering medications, insulin dose, glycemic control, body weight, and hypoglycemia at 4 years by region
in Europe.
E Europe N Europe S Europe
n (%) 676 (100) 334 (100) 689 (100)
Other glucose-lowering medication, n (%)
1 419 (62) 209 (63) 462 (67)
1 276 (41) 147 (44) 255 (37)
2 140 (21) 51 (15) 154 (22)
3 3 (0.4) 11 (3) 53 (8)
Metformin 305 (45) 187 (56) 366 (53)
Sulfonylurea 199 (29) 50 (15) 146 (21)
Glinides 16 (2) 5 (2) 91 (13)
Thiazolidinediones 20 (3) 3 (1) 23 (3)
a-Glucosidase inhibitor 0 (0) 2 (1) 25 (4)
GLP-1 receptor agonist 0 (0) 19 (6) 22 (3)
DPP-4 inhibitor 26 (4) 15 (4) 56 (8)
Other 0 (0) 1 (<1) 0 (0)
Insulin dose, U/kg
Start 0.29 (0.19) 0.20 (0.18) 0.27 (0.18)
4 year 0.58 (0.23) 0.64 (0.46) 0.52 (0.28)
HbA1c, % units
Start 9.7 (1.9) 9.1 (2.0) 9.3 (1.9)
4 year 7.3 (1.1) 7.9 (1.4) 7.7 (1.3)
Change 2.4 (2.0) 1.2 (2.1) 1.6 (2.0)
HbA1c, mmol/mol
Start 83 (21) 76 (22) 78 (21)
4 year 56 (12) 63 (15) 61 (14)
Change 26 (22) 13 (23) 17 (22)
FPG, mmol/l
Start 11.6 (2.9) 10.5 (3.1) 11.7 (3.7)
4 year 7.2 (1.8) 7.9 (2.6) 8.2 (2.7)
Change 4.5 (3.2) 2.5 (3.8) 3.5 (4.4)
PPPG, mmol/l
Start 13.6 (3.4) 13.7 (5.0) 14.0 (4.2)
4 year 8.7 (2.2) 10.5 (4.1) 9.6 (3.3)
Change 4.9 (3.7) 3.3 (5.4) 4.7 (5.0)
Documented symptomatic hypoglycemia
People with 1 event, n (%) 140 (21) 40 (12) 98 (14)
Overall rate (events/person/6 months) 1.34 (4.37) 0.35 (1.26) 0.92 (3.37)
Nocturnal rate (events/person/6 months) 0.33 (1.16) 0.07 (0.56) 0.17 (0.94)
Severe hypoglycemia
People with 1 event, n (%) 32 (5) 3 (1) 6 (1)
Overall event rate (events/person/6 months) 0.24 (1.38) 0.01 (0.09) 0.01 (0.09)
Nocturnal rate (events/person/6 months) 0.05 (0.34) 0.00 (0.05) 0.00 (0.00)
Body weight, kg
Start 83.2 (15.4) 90.7 (19.4) 79.1 (16.5)
4 year 86.1 (14.4) 92.7 (20.8) 82.2 (17.2)
Change +3.0 (7.8) +1.9 (8.3) +3.2 (7.0)
Data are mean (SD) or n (%).
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mmol/mol). Accordingly, the change in HbA1 c at 4 years
was –2.4 (2.0)% (–23 [22] mmol/mol) in E Europe but 1.2
(2.1)% (13 [23] mmol/mol) in N Europe (Table 2). HbA1c
<7.0% was achieved at 4 years by 40% of participants in E
Europe, 30% in N Europe and 32% in S Europe.
Mean (SD) FPG when starting insulin was similar in E Eur-
ope (11.7 [3.1] mmol/L) and S Europe (11.9 [3.9] mmol/L), butlower in N Europe (10.6 [3.4] mmol/l) (Fig. 2). FPG at 4 years
declined to 7.2 [1.8], 8.2 [3.7] and 7.9 [2.6] mmol/l, respectively.
Thus, change in FPG at 4 years was greatest in E Europe
(4.5 [3.2] mmol/l) and least in N Europe (2.5 [3.8] mmol/l)
(Table 2). Mean (SD) PPPG was initially 13.7 [3.6], 14.3 [5.3]
and 13.7 [4.4] mmol/l in E, N and S Europe and declined at
4 years to 8.7 [2.2], 10.5 [4.1] and 9.6 [3.3] mmol/l (Fig. 2).
The change in PPPG at 4 years was 4.9 [3.7], 3.3 [5.4] and
Fig. 2 – Evolution of HbA1c (A), FPG (B), PPPG (C), insulin dose (D) and change in body weight (E) over 4 years, with proportion of
people having at least one documented hypoglycemia episode in the 6 months before each year interval (F) by region in
Europe. Data (A-E) are mean (SD).
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and PPPG occurred in the first year (Fig. 2).
3.5. Hypoglycemia
Reported hypoglycemia by any measure tended to be highest
in E Europe and lowest in N Europe. Thus, the percentage of
participants who reported at least one hypoglycemia episode
in the last 6 months of each year ranged from a high of 22.6%
at year 2 to a low of 20.7% at year 4 in E Europe, from 12.3% at
year 1 to 8.3% at year 4 in N Europe and from 16.6% at year 1 to
14.2% at year 4 in S Europe (Fig. 2). The rate (SD) ofdocumented symptomatic hypoglycemia in E Europe in years
1–4 was 0.82 [2.28], 0.93 [2.89], 1.10 [3.38] and 1.34 [4.37]
events/person-6-months. In N Europe this was 0.51 [2.25],
0.46 [2.02], 0.30 [1.32] and 0.35 [1.26] events/person-6-
months, and in S Europe 1.01 [4.19], 1.07 [5.00], 0.76 [2.73]
and 0.92 [3.37] events/person-6-months. The rate of docu-
mented nocturnal symptomatic hypoglycemia episodes in
years 1–4 was 0.18 [0.69], 0.19 [0.82], 0.26 [0.99] and 0.33
[1.16] events/person-6-months in E Europe; 0.13 [0.75], 0.09
[0.76], 0.07 [0.54] and 0.07 [0.56] events/person-6-months in
N Europe; and 0.11 [0.70], 0.10 [0.61], 0.07 [0.42] and 0.17
[0.94] events/person-6-months in S Europe. The proportion
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hypoglycemia episode was 3.6%, 4.1%, 5.2% and 4.7% in the
last 6 months of years 1–4. In N Europe, these proportions
appear lower at 0.5%, 0.8%, 1.4% and 0.9%, as also in S Europe
at 1.0%, 0.8%, 0.5% and 0.9%.
In S Europe the incidence of documented symptomatic
hypoglycemia tended to be higher in participants taking insu-
lin alone, comparedwith the groups using oral agents (includ-
ing/not including a sulfonylurea) in addition to insulin
(Supplemental Table 3). Within the other regions incidence
was similar between the three groups. The event rates, and
incidence of severe hypoglycemia, had too high variance to
allow valid judgement between regions.3.6. Body weight change
Body weight differed at starting insulin between the three
regions (Table 1). Mean (SD) body weight at 4 years increased
most in S Europe (3.2 [7.0] kg) and in E Europe (3.0 [7.8] kg), but
by 1.9 [8.3] kg in N Europe (Table 2); most of the gain occurred
in the first year (Fig. 2).4. Discussion
The CREDIT study assessed the relationship between blood
glucose control and cardiovascular events in people with type
2 diabetes beginning any insulin regimen in real-world med-
ical practice. Overall results have been published elsewhere
[7]. From this study, we report the evolution of different insu-
lin regimens and blood glucose control change over 4 years in
E, N and S Europe, concentrating on the differences between
regions and identifying clinically relevant differences. Indeed,
it seems that the populations with type 2 diabetes starting
insulin in the three defined regions differed, with the E Euro-
pean group starting in poorer glucose control but achieving a
greater reduction in HbA1c even in the first year. The figures
for this group are not dissimilar from the overall data in the
A1chieve study, performed in non-Western countries [4]. In
that study, the authors attributed the large improvements in
glucose control as much to changes in patient education
and behavior as to the insulins themselves, largely because
in that study body weight did not increase and hypoglycemia
was minimal, independent of the insulin used. By contrast,
HbA1c in N Europe was lower when insulin was started
(though still poor) and decreased the smallest amount despite
reasonable insulin dosage, perhaps suggesting the gain in
control here was to a greater extent due to the insulin rather
than improved patient education and motivation.
Although there were marked differences in type of physi-
cian involved in starting insulin between the regions (Table 1),
these reflect some known factors such as the high number of
diabetologist specialists in Italy, the long-standing predomi-
nance of women as specialists in ex-Soviet countries and dif-
ferences in structure of care in individual countries in Europe,
with no regional pattern [13,14]. Therefore it does not seem
possible to attribute differences in baseline characteristics
or care provided when starting insulin to physician
characteristics.In the current study, weight gain was similar in the three
regions, albeit in the context of the less improvement in glu-
cose control in N Europe. Baseline body weight appeared to
differ, but is broadly consistent with WHO population data
suggesting obesity is a particular problem in two of our north-
ern European countries, intermediate in eastern Europe and
less of a problem in Italy [15], perhaps reflecting known cul-
tural differences in eating. Reported hypoglycemia was also
lower in this region. Possible explanations are differences in
attitudes to recording hypoglycemic symptoms, or because
expectations of people with diabetes and/or their clinicians
over hypoglycemia and weight gain differed.
In all regions, basal insulin was most commonly used to
initiate insulin therapy. However, patterns of insulin use did
differ over time. A prandial + basal regimen was already more
common in E Europewhen starting insulin, perhaps reflecting
the poorer initial glucose control, and became dominant with
time. This was not true of N Europe, where premix use,
already high as a starting regimen, was used by one-third of
participants by 4 years, compared with around a quarter still
on basal and a quarter on a basal bolus regimen. Premix use
could be related to patient preferences for a lower number
of injections.
Stopping insulin, presumably switching to oral therapies
in those in whom glucose control had improved, was rare in
E Europe but occurred in a significant percentage of people
in N Europe. Whether this relates to differences in physician
practice, such as a higher preference for non-insulin thera-
pies or better adherence to lifestyle changes, is unclear. In
the overall population, people stopping insulin had the best
final glucose control [7]. An alternative explanation, in a
non-interventional study like CREDIT, is the presence of
unknown differences in the patient populations in different
regions; for example, people starting insulin at the time of
an acute metabolic crisis or hospital admission for another
reason might be more likely to be able to stop it again
subsequently.
The difference in metformin and sulfonylurea use is not
unexpected; sulfonylureas were always the mainstay of oral
agent therapy in Europe until after the UKPDS study reports
[16,17], and the metformin evidence base seems to have had
a lower/slower impact in E Europe than in W Europe, where
IDF and EASD guidelines have had significant impact. How-
ever, even in the 4 years of study, some evolution is seen in
that regard, though the impact of weight gain and hypo-
glycemia may also have been significant in driving the change
in balance of oral agents.
The study has a number of limitations. Compared with the
other regions, a greater percentage of participants from E Eur-
ope were women, though this does not seem to impact dura-
tion of diabetes, body mass index and macrovascular
complications in ways that might be expected. This bias
may be related to evidence from other studies suggesting that
men in this region may have less awareness of health issues,
be more reluctant to visit doctors and have a lower level of
self-care health [8], but might also be related to recruitment
bias related to time off from employment or willingness to
share data. It is not, however, possible to know whether a
more typical proportion of men, as in the other regions,
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those from S and N Europe, or resulted in a greater deviation.
It is also possible that cultural and medical care considera-
tions affected reporting of rates of hypoglycemia, which are
known to vary widely between studies. However, our defini-
tions depend on confirmation by self-monitoring, so if any-
thing, one might expect the greater access in W Europe to
give higher rates, the opposite of what was found.
Irrespective of the regimen, the mean starting dose of
insulin was generally lower in N Europe, but the dose at
4 years was generally higher than in other regions. Again, this
suggests greater initial therapeutic caution in these countries,
with the poorer glucose control driving dose titration in time.
Examination of data pertaining to age, duration of diabetes,
body mass index or concomitant medication use does not
suggest these as explanations.
This sub-analysis is encouraging in confirming the overall
study results, that patients in all regions had a marked and
sustained (4-year) reduction in HbA1c after beginning insulin
and that the rates of hypoglycemia including severe hypo-
glycemia and nocturnal hypoglycemia were relatively modest
and did not increase with time.
In conclusion, in different parts of Europe, insulin in the
CREDIT study was initiated at different levels of glucose con-
trol, with some notable differences in evolution of insulin reg-
imens and of reported hypoglycemia. The findings may relate
to differences in medical practice and resources. Neverthe-
less, the findings are generally positive in all regions, perhaps
more so where the baseline situation was poorer, and the
improvements were generally sustained, independent of the
insulin regimen used.
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